Back to Agenda
Session 6: Payer Market Dynamics
Session Chair(s)
Stanton Mehr
Director of Content, Biosimilars Review and Report, United States
Over the next 24 months, the biosimilar industry will be entering a crucial phase in the US. Payers have played a leading role in determining whether biosimilars are covered and influencing their uptake. This session will address how payers are considering anticipated biosimilar launches for adalimumab, insulin, and ranibizumab.
Learning Objective : At the conclusion of this session, participants should be able to:
- Describe the factors that payers may consider when deciding which adalimumab biosimilar(s) or the reference product they will place on formulary
- Recognize the benefits or risks that covering a biosimilar under the pharmacy benefit (vs the medical benefit) can pose for payers
- Assess how payers will approach potential interchangeability designations among these critical biosimilar categories
Speaker(s)
Luke Greenwalt, MBA
Vice President, Market Access, Center of Excellence, IQVIA, United States
Preparing for Humira Biosimilars
James Kenney, MBA, RPH
Principal, JTKenney, LLC, United States
Payer Aspects: What It Would Mean to Cover Biosimilars Under the Pharmacy vs. Medical Benefit
Stephanie L. Ho, PHARMD
Pharmacist Evidence Analyst and Strategist, Kaiser Permanente, United States
The Potential Impact on Payers of Biosimilar Insulin
Steven Lucio, PHARMD
Senior Principal, Center for Pharmacy Practice Excellence, Vizient Inc., United States
Improving Hospital and Health System Uptake of Biosimilars
Have an account?